Digene Corp.

Yes, we know. The life science venture shakeout isn’t over yet. It’ll get smaller before it gets bigger. That was the drumbeat Financings of the Fortnight heard as it made the rounds at J.P. Morgan ea

There are many potential entry points to the molecular diagnostics business: biomarker discovery, laboratory operations, instrumentation development, even disease management. Companies in these variou

2009 proved a difficult year for the medical device industry as the industry wrestled with an economic crisis that (hopefully) is behind us and health care reform yet to come. by EBI's Medical Device

2006’s most intriguing Series As reflect VCs’ continued emphasis on risk reduction through re-profiling in biotech, and big gains in funding for diagnostics and device start-ups. By Christopher Morris